Promoter holding
64.27%
DV
D Vijay Pharma Private Limited - Due diligence report
A 360° intelligence report on Dvijay Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Dvijay Pharma — 360° Intelligence Report
Generated from MCA filings & public records93/100
Trust Score
Low Risk
Dvijay Pharma is assessed as Low Risk with a Trust Score of 93/100. Dvijay Pharma is an active private limited indian non-government company incorporated in 2003, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 23 Jul 2026 from the latest processed filings. D Vijay Pharma Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
93/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 60/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (B).
Charges position: 3 open (43.01 cr) · 1 satisfied (99.00 Lakh).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Axis Bank Limited | 1 | 48.0 cr |
| Others | 1 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
| The Nasik Merchants Co-Op Bank Ltd | 1 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 2 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| DHAVAL UPENDRA DINANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MEERA UPENDRA DINANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIJAY JAMNADAS DINANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| URMI VIJAY DINANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| UPENDRA DINANI JAMANADAS | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 1 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: URMI VIJAY DINANI (Managing Director) · UPENDRA DINANI JAMANADAS (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Asset base grew 24% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 23+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 0.86 in a year.
3 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 43.01 cr already registered.
- Compliance record supports lending.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
25 Jun 2025
Charge created
Others - 5.00 cr
31 Mar 2025
Latest balance sheet
Filed with ROC
01 May 2024
Director appointed
DHAVAL UPENDRA DINANI (Director)
03 Jun 2023
Charge created
Hdfc Bank Limited - 2.01 cr
31 Mar 2019
Share transfer (FY 2019)
5000.00000000 shares to PINK PHARMACY PRIVATE LIMITED
05 Oct 2011
Securities allotted
20000.00 Equity Shares - 2.00 Lakh raised
13 Jul 2010
Charge satisfied
The Nasik Merchants Co-Op Bank Ltd
09 Jun 2010
Charge created
Axis Bank Limited - 36.00 cr
02 Mar 2007
Director appointed
UPENDRA DINANI JAMANADAS (Managing Director)
12 Feb 2004
Charge created
The Nasik Merchants Co-Op Bank Ltd - 99.00 Lakh
06 Jun 2003
Incorporated
Registered with Roc Mumbai Ii
Director appointed
MEERA UPENDRA DINANI (Director)
Director appointed
VIJAY JAMNADAS DINANI (Director)
Director appointed
URMI VIJAY DINANI (Managing Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of B from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Kasturi International Private Limited | U74999DL1992PTC048059 | Delhi, Delhi, India |
| Brio Interactive Technologies Limited | U72200DL2012PLC242110 | Okhala, Delhi, India |
| Ambica Ispat Private Limited | U27109TG1990PTC011816 | Secunderabd, Andhra Pradesh, Telangana, India |
| Ksp Electro Engineering (India) Private Limited | U31103WB2010PTC148671 | Barasat - I, West Bengal, India |
| Reenav Pharma Private Limited | U74999MH2018PTC308208 | Mumbai, Maharashtra, India |
| Super Specialities Pharma Warehousing & Logistics Private Limited | U74900MH2012PTC233473 | Mumbai, Maharashtra, India |
| Fenda Audio India Pvt Ltd | U32309DL2005PTC143072 | New Delhi, Delhi, India |
| Agarwal Steel Private Limited | U27200WB2013PTC201977 | Kolkata, West Bengal, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Dvijay Pharma before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Dvijay Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Dvijay Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 93/100, distress signals and MSME payment-delay disclosures - know whether Dvijay Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Dvijay Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Dvijay Pharma an active company?
Dvijay Pharma has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Dvijay Pharma financially healthy?
Dvijay Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Dvijay Pharma?
Its overall Trust Score is 93/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Dvijay Pharma?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 5 active director(s) are on record.
Does Dvijay Pharma have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Dvijay Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Dvijay Pharma?
Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
